Ligand id: 7384

Name: blinatumomab

No information available.
Summary of Clinical Use
In December 2014 the FDA approved blinatumomab for use in the treatment of Philadelphia chromosome-negative (Ph-) precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL. Blinatumomab is undergoing clinical trial for other forms of ALL and lymphoma. A list of current trials can be viewed at In the European Union blinatumomab is a EMA designated orphan drug that can be used to treat Ph- relapsed or refractory B-cell precursor ALL.
In July 2017, the FDA expanded approval to include treatment of relapsed or refractory B-cell precursor ALL in adults and children, based on data from the Phase 3 TOWER study that shows that blinatumomab single agent therapy exhibits superior improvement in median overall survival over standard of care chemotherapy. This is the first single-agent immunotherapy approved to treat patients with Ph- relapsed or refractory B-cell precursor ALL. March 2018 saw FDA approval expanded further to include treatment of adult and pediatric patients with B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD), based on the BLAST trial (NCT01207388) [3].
Mechanism Of Action and Pharmacodynamic Effects
Structurally, blinatumomab carries peptide sequences which interact with CD3e (part of the T cell receptor, TCR, of T cells) and CD19 found on B cells. Functionally, the antibody binds epitopes on T and B cells bringing them together, activating the T cells and directing their cytotoxic effects towards malignant B cells [5].
External links